2022 SOHO Annual Meeting | FOCUS on MDS
The 10th Annual Meeting of the Society of Hematologic Oncology was held from September 28–October 1, 2022. In this section of the meeting, we focused on updates presented on myelodysplastic syndromes (MDS).
Advertisement
A study showed "unexpected" results related to race and MDS survival...
Nearly a third (30%) of patients with higher-risk MDS have an overexpression of the RARA gene...
The classification process is mainly based on two processes, class discovery and class prediction...
Phillip Scheinberg, MD, PhD, discusses myelodysplastic syndromes at the 2022 SOHO Annual Meeting...
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
Blood Cancers Today interviewed Dr. Diez-Campelo after her presentation titled, “Treatment of Lower Risk MDS.”
Researchers retrospectively assessed 135 untreated patients with MDS who later developed HMA-F...
Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting...
The outcomes of AML transformation after HMA-failure MDS remain extremely poor...
Azacitidine is the current standard of care, and magrolimab is a monoclonal antibody blocking CD47 expression...
During the 2022 SOHO Annual Meeting, Jacqueline S. Garcia, MD, discussed immunotherapies for myelodysplastic syndromes...
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Dr. Garcia-Manero talks about what a “total approach” to MDS means to him...
The number of HSCTs performed for MDS is increasing, yet HSCT remains under-utilized for MDS...
Guillermo Garcia-Manero, MD, was honored during the society’s 10th annual meeting in Houston, Texas...
The study sought to understand the characteristics and molecular profile of h-MDS in comparison with n-MDS...
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.